Willingness to Participate in Testing, Contact Tracing, and Taking the COVID-19 Vaccine among Community Members in a Southwestern State in Nigeria
DOI:
https://doi.org/10.31646/gbio.106Keywords:
COVID-19, COVID-19 testing, disclosure of COVID-19 contacts, Vaccine, Coronavirus.Abstract
Background: This study aimed to describe community members’ willingness to participate in COVID-19 testing, contact tracing, and acceptance of the COVID-19 vaccine in a Southwestern state in Nigeria.
Methods: We conducted a descriptive cross-sectional study using an interviewer-administered questionnaire. Community members aged 15 years and above were studied using a multi-stage sampling technique. One question each was asked on respondents’ willingness for COVID-19 testing, contact disclosure, and willingness to take the COVID-19 vaccine. Descriptive statistics and chi-square tests were conducted on willingness for COVID-19 testing, contact disclosure and taking the COVID-19 vaccine. Multivariate logistic analyses were performed on variables that were significant at the bivariate level. P-values <0 .05 were statistically significant.
Results: Among the 691 respondents, 244 (35.3%) were aged 21-29 years, 436 (73.2%) were willing to take the COVID-19 test, 458 (66.3%) were willing to disclose contacts’ names if tested positive, and 434 (74.8%) were willing to take the COVID-19 vaccine. Persons who earned less than 30,000 naira (U.S.$78.95) monthly had two times the odds to be willing to take the COVID-19 test (OR=2.031, (95%CI=1.117-3.694), p = 0.02). Persons who had completed 10-12 years of education had three times the odds to be willing to disclose contacts if tested positive for COVID-19 (OR=2.628, (95%CI=1.301-5.308), p=0.007). Persons whose financial status worsened, i.e., those whose income had reduced during the COVID-19 pandemic, had three times the odds to be willing to take the COVID-19 vaccine (OR=2.686, (95%CI=1.363-6.448), p=0.006).
Conclusion: Interventions to improve willingness for COVID-19 testing and taking the COVID-19 vaccine should be targeted towards those wealthy individuals.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 The Author(s)
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Accepted 2021-04-10
Published 2021-05-31